Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Acquired by Barclays PLC

Barclays PLC increased its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 353.6% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 54,166 shares of the company’s stock after purchasing an additional 42,224 shares during the period. Barclays PLC owned approximately 0.09% of Ginkgo Bioworks worth $531,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in DNA. SBI Securities Co. Ltd. acquired a new stake in Ginkgo Bioworks during the 4th quarter worth $29,000. KBC Group NV acquired a new position in Ginkgo Bioworks during the fourth quarter worth $31,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Ginkgo Bioworks in the fourth quarter valued at about $46,000. Palumbo Wealth Management LLC acquired a new position in Ginkgo Bioworks during the fourth quarter worth about $144,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Ginkgo Bioworks during the 4th quarter worth approximately $154,000. Hedge funds and other institutional investors own 78.63% of the company’s stock.

Ginkgo Bioworks Stock Up 6.4 %

Ginkgo Bioworks stock opened at $7.88 on Friday. The firm has a market capitalization of $457.02 million, a PE ratio of -0.60 and a beta of 1.29. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.00 and a 52 week high of $38.58. The firm’s 50-day simple moving average is $7.13 and its 200 day simple moving average is $9.09.

Ginkgo Bioworks (NYSE:DNA) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.35). Ginkgo Bioworks had a negative return on equity of 58.54% and a negative net margin of 298.78%. The business had revenue of $48.32 million during the quarter, compared to analyst estimates of $38.70 million. On average, research analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 EPS for the current fiscal year.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.